**Massachusetts Biopharma Sector Sees Year-Over-Year Job Declines**
Massachusetts’ life sciences research and development sector experienced a 1.7% employment decline in 2024 — the first annual drop in recent memory, according to the newly released Industry Snapshot report from MassBio. The year also marked the second consecutive decline in biomanufacturing jobs amid a broader industry slowdown. Venture capital funding reached its lowest level since 2017.
Despite the downturn in funding, Massachusetts maintained its position as a dominant player in the biotech industry, attracting nearly 25% of all U.S. venture capital investment in the sector. MassBio emphasized the resilience of the state’s biopharmaceutical workforce and noted several factors contributing to its long-term strength, including a high concentration of biotechnology companies, seasoned venture capital firms, strong global pharmaceutical presence, a well-trained talent pool, dedicated innovation infrastructure, and ongoing support from state government.
“Biotech is Massachusetts,” said Kendalle Burlin O’Connell, CEO and President of MassBio. “Every day, our companies work to improve human health and deliver for patients, which is why it’s critical we navigate today’s headwinds with collaboration and resilience.”
While timelines for investor recovery remain uncertain, Massachusetts’ robust ecosystem continues to make it one of the most well-positioned regions in the country to weather economic fluctuations in the biopharma industry.
